• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

pSivida launches Phase III study of its micro-sized eye implant

July 5, 2013 By drugdelivery

pSivida launches Phase III of its drug/device combo for vision loss r

pSivida (NSDQ:PSDV) started recruiting patients in a Phase III U.S. trial for its eyelash-sized drug/device combination, an implant designed to treat ocular swelling that can lead to blindness.

The micro-implant treats uveitis, an inflammation of the middle eye layer that can lead to vision loss. pSivida said the study is the 1st of 2 planned efficacy trials required by the FDA before commercial launch.

The 2 trials are slated to take place at 15 sites in the States and possibly at additional locations internationally. If successful, the company plans to submitting the data in a New Drug Application to the FDA.

Watertown, Mass.-based pSivida also licenses the tiny eye implant to Alimera Sciences (NSDQ:ALIM), which has already begun selling its version of the product, called Iluvien, in 6 countries in Europe.

"We are extremely pleased that our 1st 3 U.S. clinical sites have begun recruiting patients for this trial," said CEO Dr. Paul Ashton in prepared remarks. "We are very optimistic that our micro-insert will be efficacious for the treatment of posterior uveitis with a more favorable risk/benefit profile, fewer side effects and greater ease of administration than Retisert, our current FDA-approved product for the treatment of the same disease."

pSivida recently hit a 52-week high on Wall Street based on speculation from a Seeking Alpha blogger that it’s ripe for an acquisition this year.

Filed Under: Drug-Device Combinations Tagged With: Alimera Sciences, Clinical Trials, pSivida Corp.

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS